Prodrugs for amidines: Synthesis and anti-Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan

Journal of Medicinal Chemistry

Volumn 42, Issue 19, 1999, Pages 3994-4000

  Rahmathullah, Syed M ^a   Hall, James Edwin ^b,c   Bender, Brendan C ^a   McCurdy, Donald R ^d   Tidwell, Richard R ^c,d   Boykin, David W ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDINE; CARBAMIC ACID DERIVATIVE; CHLOROFORMIC ACID ETHYL ESTER; FURAN DERIVATIVE; PENTAMIDINE; PRODRUG; REAGENT; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG SYNTHESIS; DRUG TRANSFORMATION; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; PNEUMOCYSTIS CARINII; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; BENZAMIDINES; CARBAMATES; MODELS, CHEMICAL; PNEUMOCYSTIS; PRODRUGS; RATS;

EID: 0033598329     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990237+     Document Type: Article

References (40)

1. Jones, J. L.; Hansen, D. L.; Dworkin, M. S.; Alderton, D. L.; Fleming, P. L., Kaplan, J. E.; Ward, J. Surveillance for AIDS-Defining Opportunistic Illnesses, 1992-1997. MMWR 1999, 48, 1-22.
2. (a) Sepkowitz, K. A.; Armstrong, D. Treatment of opportunistic infections in AIDS. Lancet 1995, 346, 588-589.
3. (b) Montgomery, A. B.; Luce, J. M.; Turner, J.; Lin, E. T.; Debs, R. J.; Corkery, K. J.; Brunnette, F. N.; Hopewell, P. C. Lancet 1987, 8, 480.
4. Boykin, D. W.; Kumar A.; Spychala, J.; Zhou, M.; Lombardy, R.; Wilson, W. D.; Dykstra, C. C.; Jones, S. K.; Hall, J. E.; Tidwell, R. R.; Laughton, C.; Nunn, C. M.; Neidle, S. Dicationic diarylfurans as anti-Pneumocystis carinii agents. J. Med. Chem. 1995, 36, 912-916.
5. Tidwell, R. R.; Jones, S. K.; Naimen, N. A.; Berger, L. C.; Brake, W. B.; Dykstra, C. C.; Hall, J. E. Activity of cationically substituted bis-benzimidazoles against experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 1993, 37, 1713.
6. Lombardy, R. L.; Tanious, F. A.; Ramachandran, K.; Tidwell, R. R.; Wilson, W. D. Synthesis and DNA interactions of benzimidazole dications which have activity against opportunistic infections. J. Med. Chem. 1996, 39, 1452-1452.
7. Kumar, A.; Boykin, D. W.; Wilson, W. D.; Jones, S. K.; Bender, B. K.; Dykstra, C. C.; Hall, J. E.; Tidwell, R. R. Anti-Penumocystis carinii pneumonia activity of dicationic 2,4-diarylpyrimidines. Eur. J. Med. Chem. 1996, 31, 767-773.
8. Das, B. P.; Boykin, D. W. Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans. J. Med. Chem. 1977, 20, 531-536.
9. Steck, E. A.; Kinnamon, K. K.; Davidson, D. E.; Duxbury, R. E.; Johnson, A. J.; Masters, R. E. Trypanosoma rhodescience: Evaluation of the action of 2,5-bis(4-guanylphenyl)furan dihydrochloride. Exp. Parasitol. 1982, 53, 133-144.
10. Boykin, D. W.; Kumar, A.; Xiao, G.; Wilson, W. D.; Bender, B. C.; McCurdy, D. F.; Hall, J. E.; Tidwell, R. R. 2,5-Bis[4-(alkylamidino)phenyl]furans as anti-pneumocystis carinii agents. J. Med. Chem. 1998, 41, 124-129.
11. Bundgaard, H. In Design of Prodrugs; Bundgaard, H., Ed.; Elsevier: Amsterdam, The Netherlands, 1985; pp 1-92.
12. Bundgaard, H. In A Textbook of Drug Design and Development; Krogsgaard-Larsen, P., Bundgaard, H., Eds.; Harwood Academic Publ.: Switzerland, 1991; pp 113-191.
13. Friis, G. J.; Bundgaard, H. In A Textbook of Drug Design and Development, 2nd ed.; Krogsgaard-Larsen, P., Liljefors, T., Madsen, U., Eds.; Overseas Publ: Amsterdam, The Netherlands, 1996; pp 351-385.
14. Digenis, G. A.; Swintosky, J. V. Drug latentiation. Handbook Exp. Pharmacol. 1975, 28, 86-112.
15. Sinkula, A. A.; Yalkowsky. Rationale for design of biologically reversible drug derivatives: Prodrugs. J. Pharm. Sci. 1975, 64, 181-210.
16. Pitman, I. H. Prodrugs of amides, imides and amines. Med. Res. Rev. 1981, 1, 189-214.
17. Bundgaard, H.; Nielsen, N. M. Esters of N,N-Disubstituted 2-Hydroxyacetamides as a Novel Highly Biolabile Prodrug Type for Carboxylic Acid Agents. J. Med. Chem. 1987, 30, 451-454.
18. Shahrokh, Z.; Lee, E.; Olivero, A. G.; Matamoros, R. A.; Roborage, K. D.; Lee, A.; Weise, K. J.; Blackburn, B. K.; Powell, M. F. Stability of alkoxycarbonylamidine prodrugs. Pharm. Res. 1998, 15, 434-441.
19. Weller, T.; Alieg, L.; Beresini, M.; Blackburn; B.; Bunting, S.; Hadvary, P.; Muller, M. H.; Knopp, D.; Levet-Trafit, B.; Lipari, M. T.; Modi, N. B.; Muller.; Refino, C. J.; Schmitt, M.; Schonholzer, P.; Weiss, S.; Steiner, B. Orally Active Fibrinogen Receptor Antagonists 2. Amidoximes as Prodrugs of Amidines. J. Med. Chem. 1996, 39, 3139-3146.
20. Boykin, D. W.; Kumar, A.; Hall, J. E.; Bender, B. C.; Tidwell, R. R. Anti-pneumocystis carinii activity of bis-amidoximes and bis-O-alkylamidoximes prodrugs. Bioorg. Med. Chem. Lett. 1996, 6, 3017-3020.
21. Verbiscar, A. J.; Abood, L. G. Carbamate Ester Latentiation of Physiologically Active Amines. J. Med. Chem. 1970, 13, 1176-1179.
22. Alexander, J.; Cargill, R.; Michelson, S. R.; Schwam, H. (Acyloxy)alkyl carbamates as Novel Bioreversible Prodrugs for Amines. J. Med. Chem. 1988, 31, 318-322.
23. Muller, T. H.; Weisenberger, H.; Brickl, R.; Narjes, H.; Himmelsbach, F.; Krause, J. Profound and Sustained Inhibition of Platelet Aggregation by Fradafiban, a Nonpeptide Platelet Glcoprotein Iib/IIIa Antagonist, and its Orally Active Prodrug, Lefradafiban, in Men. Circulation 1997, 96, 1130-1138.
24. Sakamoto, F.; Ikeda, S.; Tsukamoto, G. Studies on Prodrugs. II. Preparation and Characterization of (5-Substituted 2-oxo-1,3-dioxolen-4-yl)methyl Esters of Ampicillin. Chem. Pharm. Bull. 1984, 32, 2241-2248.
25. Alexander, J.; Bindra, D. S.; Glass, J. D.; Holahan, M. A.; Renyer, M. L.; Rork, G. S.; Sitko, G. R.; Stupienski, R. F.; Veerapanane, H.; Cook, J. J. Investigation of (Oxodioxolenyl)methyl Carbamates as Nonchiral Bioreversible Prodrug Moieties for Chiral Amines. J. Med. Chem. 1996, 39, 480-486.
26. Sakamoto, F.; Ikeda, S.; Hirayama, R.; Moriyama, M.; Sotomura, M.; Tsukamoto, G. Studies on Prodrugs VI. Preparation and Characterization of N-(5-substitued-2-oxo-1,3-dioxol-4-yl)methylnorfloxacin. Chem. Pharm. Bull. 1987, 35, 642-646.
27. Sakamoto, F.; Ikeda, S.; Kondo, H.; Tsukamoto, G. Studies on Prodrugs IV, Preparation and Characterization of N-(5-substitued-2-oxo-1,3-dioxol-4-yl)methyl ester of mecillinam. Chem. Pharm. Bull. 1985, 33, 4870-4877.
28. Miyauchi, M.; Suzuki, K.; Endo, R.; Kawamoto, I. Studies on Penem and Carbapenem. II. An Improved Synthesis of Orally Active Penem Antibiotic (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl (5R,6S)-2-(2-Fluoroethylthio)-6-[(1R)-1-hydroxyethyl]penem-3-carboxylate. Chem. Pharm. Bull. 1990, 38, 1077-1078.
29. Alpegiani, M.; Zarini, F.; Perrone, E. On the preparation of 4-hydroxymethyl-5-methyl-1,3-dioxol-2-one. Synth. Commun. 1992, 22, 1277-1282.
30. Bajic, M.; Kumar, A.; Boykin, D. W. Synthesis of 2,5-bis(4-cyanophenyl)furan. Heterocycl. Commun. 1996, 2, 135-140.
31. Olofson, R. A.; Martz, J. T.; Senet, J.-P.; Piteau, M.; Malfroot, T. A New Reagent for the Selective, High-Yield N-Dealkylation of Tertiary Amines: Improved Syntheses of Naltrexone and Nalbuphine. J. Org. Chem. 1984, 49, 2081-2082.
32. Olofson, R. A. New, useful reactions of novel haloformates and related reagents. Pure Appl. Chem. 1988, 60, 1715-1724.
33. Millan, D. S.; Prager, R. F. The Dealkylation of Tertiary Aliphatic Amines with Phenyl Chlorothionoformate. Tetrahedron Lett. 1998, 39, 4387-4390.
34. Alexander, J.; Fromtling, R. A.; Bland, J. A.; Pelak, B. A.; Gilfillan, E. C. (Acyloxy)alkyl carbamate prodrugs of Norfloxacin. J. Med. Chem. 1991, 34, 78-81.
35. Lin, Y. I.; Bitha, P.; Li, Z.; Sakya, S. M.; Strohmeyer, T. W.; Lang, S. A., Jr.; Yang, Y.; Bhachech, N.; Weiss, W. J.; Petersen, P. J.; Jacobus, N. V.; Bush, K.; Testa, R. T. Mono and bis doublè ester prodrugs of novel aminomethyl-THF 1b-methylcarbapenems. Bioorg. Med. Chem. Lett. 1997, 7, 1811-1816.
36. Jones, S. K.; Hall, J. E.; Allen, M. A.; Morrison, S. D.; Ohemeng, K. A.; Reddy, V. V.; Geratz, J. D.; Tidwell, R. R. Novel pentamidine analogues in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 1990, 34, 1026-1030.
37. Hall, J. E.; Kerrigan, J. E.; Ramachandran, K.; Bender, B. C.; Stanko, J. P.; Jones, S. K.; Patrick, D. A.; Tidwell, R. R. Anti-Pneumocystis Activities of Aromatic Diamidoxime Prodrugs. Antimicrob. Agents Chemother. 1998, 42, 666-674.
38. Tidwell, R. R.; Jones, S. K.; Geratz, J. D.; Ohemeng, K. A.; Cory, M.; Hall, J. E. Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. J. Med. Chem. 1990, 33, 1252-1257.
39. Saito, A.; Nakashima, M. Pharmacokinetic study of Lenampicillin (KBT-1585) in Healthy Volunteers. Antimicrob. Agents. Chemother. 1986, 29, 948-950
40. Maehara, K.; Okamoto, Y.; Kishimoto, Y.; Kitajima, H.; Uwamori, H.; Iida, Y.; Yoshioko, M.; Mase, K.; Yasunaga, K.; Ueda, Y.; Okubo, H. Clinical studies on Lenampicillin (KBT-1585). Chemotherapy (Tokyo) 1984, 32 (Suppl. 8), 337-346.